A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy

April Y. Maa, William J Feuer, C. Quentin Davis, Ensa K. Pillow, Tara D. Brown, Rachel M. Caywood, Joel E. Chasan, Stephen R. Fransen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aims: To evaluate the performance of the RETeval device, a handheld instrument using flicker electroretinography (ERG) and pupillography on undilated subjects with diabetes, to detect vision-threatening diabetic retinopathy (VTDR). Methods: Performance was measured using a cross-sectional, single armed, non-interventional, multi-site study with Early Treatment Diabetic Retinopathy Study 7-standard field, stereo, color fundus photography as the gold standard. The 468 subjects were randomized to a calibration phase (80%), whose ERG and pupillary waveforms were used to formulate an equation correlating with the presence of VTDR, and a validation phase (20%), used to independently validate that equation. The primary outcome was the prevalence-corrected area under the receiver operating characteristic (ROC) curve for the detection of VTDR. Results: The area under the ROC curve was 0.86 for VTDR. With a sensitivity of 83%, the specificity was 78% and the negative predictive value was 99%. The average testing time was 2.3. min. Conclusions: With a VTDR prevalence similar to that in the US, the RETeval device will identify about 75% of the population as not having VTDR with 99% accuracy. The device is simple to use, does not require pupil dilation, and has a short testing time.

Original languageEnglish (US)
JournalJournal of Diabetes and its Complications
DOIs
StateAccepted/In press - Sep 24 2015

Fingerprint

Diabetic Retinopathy
Equipment and Supplies
Electroretinography
ROC Curve
Photography
Pupil
Calibration
Dilatation
Color
Sensitivity and Specificity
Population

Keywords

  • Diabetic eye exam
  • Diabetic macular edema
  • Diabetic retinopathy
  • ERG
  • Pupillography
  • Retinal diagnostic test

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Maa, A. Y., Feuer, W. J., Davis, C. Q., Pillow, E. K., Brown, T. D., Caywood, R. M., ... Fransen, S. R. (Accepted/In press). A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy. Journal of Diabetes and its Complications. https://doi.org/10.1016/j.jdiacomp.2015.12.005

A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy. / Maa, April Y.; Feuer, William J; Davis, C. Quentin; Pillow, Ensa K.; Brown, Tara D.; Caywood, Rachel M.; Chasan, Joel E.; Fransen, Stephen R.

In: Journal of Diabetes and its Complications, 24.09.2015.

Research output: Contribution to journalArticle

Maa, April Y. ; Feuer, William J ; Davis, C. Quentin ; Pillow, Ensa K. ; Brown, Tara D. ; Caywood, Rachel M. ; Chasan, Joel E. ; Fransen, Stephen R. / A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy. In: Journal of Diabetes and its Complications. 2015.
@article{5426e812e231469e885c96c07965e251,
title = "A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy",
abstract = "Aims: To evaluate the performance of the RETeval device, a handheld instrument using flicker electroretinography (ERG) and pupillography on undilated subjects with diabetes, to detect vision-threatening diabetic retinopathy (VTDR). Methods: Performance was measured using a cross-sectional, single armed, non-interventional, multi-site study with Early Treatment Diabetic Retinopathy Study 7-standard field, stereo, color fundus photography as the gold standard. The 468 subjects were randomized to a calibration phase (80{\%}), whose ERG and pupillary waveforms were used to formulate an equation correlating with the presence of VTDR, and a validation phase (20{\%}), used to independently validate that equation. The primary outcome was the prevalence-corrected area under the receiver operating characteristic (ROC) curve for the detection of VTDR. Results: The area under the ROC curve was 0.86 for VTDR. With a sensitivity of 83{\%}, the specificity was 78{\%} and the negative predictive value was 99{\%}. The average testing time was 2.3. min. Conclusions: With a VTDR prevalence similar to that in the US, the RETeval device will identify about 75{\%} of the population as not having VTDR with 99{\%} accuracy. The device is simple to use, does not require pupil dilation, and has a short testing time.",
keywords = "Diabetic eye exam, Diabetic macular edema, Diabetic retinopathy, ERG, Pupillography, Retinal diagnostic test",
author = "Maa, {April Y.} and Feuer, {William J} and Davis, {C. Quentin} and Pillow, {Ensa K.} and Brown, {Tara D.} and Caywood, {Rachel M.} and Chasan, {Joel E.} and Fransen, {Stephen R.}",
year = "2015",
month = "9",
day = "24",
doi = "10.1016/j.jdiacomp.2015.12.005",
language = "English (US)",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy

AU - Maa, April Y.

AU - Feuer, William J

AU - Davis, C. Quentin

AU - Pillow, Ensa K.

AU - Brown, Tara D.

AU - Caywood, Rachel M.

AU - Chasan, Joel E.

AU - Fransen, Stephen R.

PY - 2015/9/24

Y1 - 2015/9/24

N2 - Aims: To evaluate the performance of the RETeval device, a handheld instrument using flicker electroretinography (ERG) and pupillography on undilated subjects with diabetes, to detect vision-threatening diabetic retinopathy (VTDR). Methods: Performance was measured using a cross-sectional, single armed, non-interventional, multi-site study with Early Treatment Diabetic Retinopathy Study 7-standard field, stereo, color fundus photography as the gold standard. The 468 subjects were randomized to a calibration phase (80%), whose ERG and pupillary waveforms were used to formulate an equation correlating with the presence of VTDR, and a validation phase (20%), used to independently validate that equation. The primary outcome was the prevalence-corrected area under the receiver operating characteristic (ROC) curve for the detection of VTDR. Results: The area under the ROC curve was 0.86 for VTDR. With a sensitivity of 83%, the specificity was 78% and the negative predictive value was 99%. The average testing time was 2.3. min. Conclusions: With a VTDR prevalence similar to that in the US, the RETeval device will identify about 75% of the population as not having VTDR with 99% accuracy. The device is simple to use, does not require pupil dilation, and has a short testing time.

AB - Aims: To evaluate the performance of the RETeval device, a handheld instrument using flicker electroretinography (ERG) and pupillography on undilated subjects with diabetes, to detect vision-threatening diabetic retinopathy (VTDR). Methods: Performance was measured using a cross-sectional, single armed, non-interventional, multi-site study with Early Treatment Diabetic Retinopathy Study 7-standard field, stereo, color fundus photography as the gold standard. The 468 subjects were randomized to a calibration phase (80%), whose ERG and pupillary waveforms were used to formulate an equation correlating with the presence of VTDR, and a validation phase (20%), used to independently validate that equation. The primary outcome was the prevalence-corrected area under the receiver operating characteristic (ROC) curve for the detection of VTDR. Results: The area under the ROC curve was 0.86 for VTDR. With a sensitivity of 83%, the specificity was 78% and the negative predictive value was 99%. The average testing time was 2.3. min. Conclusions: With a VTDR prevalence similar to that in the US, the RETeval device will identify about 75% of the population as not having VTDR with 99% accuracy. The device is simple to use, does not require pupil dilation, and has a short testing time.

KW - Diabetic eye exam

KW - Diabetic macular edema

KW - Diabetic retinopathy

KW - ERG

KW - Pupillography

KW - Retinal diagnostic test

UR - http://www.scopus.com/inward/record.url?scp=84955277064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955277064&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2015.12.005

DO - 10.1016/j.jdiacomp.2015.12.005

M3 - Article

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

ER -